Damora Therapeutics, Inc.

Direct answer

Damora Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DMRA.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as...

Can you invest in Damora Therapeutics, Inc.?

Yes. Damora Therapeutics, Inc. trades publicly on NASDAQ as DMRA.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Damora Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.